Effects of Dutasteride on the Expression of Genes Related to Androgen Metabolism and Related Pathway in Human Prostate Cancer Cell Lines

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2007 Jul 20

PMID 17636412

Citations 13

Authors

Michela Biancolella

Alessandra Valentini

Daniela Minella

Lucia Vecchione

Franca DAmico

Giovanni Chillemi

Paolo Gravina

Susana Bueno

Gianluca Prosperini

Alessandro Desideri

Giorgio Federici

Sergio Bernardini

Giuseppe Novelli

Affiliations

Soon will be listed here.

Abstract

Androgens play an important role in controlling the growth of the normal prostate gland and in the pathogenesis of benign prostate hyperplasia, and prostate cancer. Although testosterone is the main androgen secreted from the testes, dihydrotestosterone (DHT), a more potent androgen converted from testosterone by 5alpha-reductase isozymes, type I and II, is the major androgen in the prostate cells. The aim of this study is to investigate the cellular and molecular effects of dutasteride, a potent inhibitor of 5alpha-reductase type I and type II, in androgen-responsive (LNCaP) and androgen-unresponsive (DU145) human prostate cancer(PCa) cell lines. The expression pattern of 190 genes, selected on the basis of their proved or potential role in prostate cancerogenesis related to androgen signalling, were analysed using a low density home-made oligoarray (AndroChip 2). Our results show that dutasteride reduces cell viability and cell proliferation in both cell lines tested. AndroChip 2 gene signature identified in LNCaP a total of 11 genes differentially expressed (FC >or= +/-1.5). Eight of these genes, were overexpressed and three were underexpressed. Overexpressed genes included genes encoding for proteins involved in biosynthesis and metabolism of androgen (HSD17B1;HSD17B3;CYP11B2), androgen receptor and androgen receptor co-regulators (AR;CCND1), and signal transduction(ERBB2; V-CAM; SOS1) whereas, underexpressed genes (KLK3; KLK2; DHCR24) were androgen-regulated genes (ARGs). No differentially expressed genes were scored in DU145. Microarray data were confirmed by quantitative real-time PCR assay (QRT-PCR). These data offer a selective genomic signature for dutasteride treatment in prostate epithelial cells and provide important insights in prostate cancer pathophysiology.

Citing Articles

DHCR24 in Tumor Diagnosis and Treatment: A Comprehensive Review.

Fu X, Wang Z Technol Cancer Res Treat. 2024; 23:15330338241259780.

PMID: 38847653 PMC: 11162140. DOI: 10.1177/15330338241259780.

Steroid 5α-Reductase Type I Induces Cell Viability and Migration via Nuclear Factor-κB/Vascular Endothelial Growth Factor Signaling Pathway in Colorectal Cancer.

Wei R, Zhong S, Qiao L, Guo M, Shao M, Wang S Front Oncol. 2020; 10:1501.

PMID: 32983992 PMC: 7484213. DOI: 10.3389/fonc.2020.01501.

Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.

Hilborn E, Stal O, Jansson A Oncotarget. 2017; 8(18):30552-30562.

PMID: 28430630 PMC: 5444764. DOI: 10.18632/oncotarget.15547.

Neuroprotective effects of estrogens: the role of cholesterol.

Peri A J Endocrinol Invest. 2015; 39(1):11-8.

PMID: 26084445 DOI: 10.1007/s40618-015-0332-5.

Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.

Mostaghel E Int J Biol Sci. 2014; 10(6):602-13.

PMID: 24948873 PMC: 4062953. DOI: 10.7150/ijbs.8844.

References

Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D . Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004; 172(4 Pt 1):1314-7. DOI: 10.1097/01.ju.0000139320.78673.2a. View

Isaacs J . The biology of hormone refractory prostate cancer. Why does it develop?. Urol Clin North Am. 1999; 26(2):263-73. DOI: 10.1016/s0094-0143(05)70066-5. View

Mitchell S, Abel P, Ware M, Stamp G, Lalani E . Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int. 2000; 85(7):932-44. DOI: 10.1046/j.1464-410x.2000.00606.x. View

Negri-Cesi P, Poletti A, Colciago A, Magni P, Martini P, Motta M . Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate. 1998; 34(4):283-91. DOI: 10.1002/(sici)1097-0045(19980301)34:4<283::aid-pros6>3.0.co;2-i. View

GROSSMANN M, Huang H, Tindall D . Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001; 93(22):1687-97. DOI: 10.1093/jnci/93.22.1687. View

Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A . Androgen receptors in prostate cancer. J Urol. 2003; 170(4 Pt 1):1363-9. DOI: 10.1097/01.ju.0000075099.20662.7f. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Pietras R, Arboleda J, Reese D, Wongvipat N, Pegram M, Ramos L . HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995; 10(12):2435-46. View

DE Longueville F, Atienzar F, Marcq L, Dufrane S, Evrard S, Wouters L . Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol Sci. 2003; 75(2):378-92. DOI: 10.1093/toxsci/kfg196. View

10.

Stoner E . 5alpha-reductase inhibitors/finasteride. Prostate Suppl. 1996; 6:82-7. View

11.

Schmidt L, Murillo H, Tindall D . Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. J Androl. 2004; 25(6):944-53. DOI: 10.1002/j.1939-4640.2004.tb03166.x. View

12.

Xu Y, Dalrymple S, Becker R, Denmeade S, Isaacs J . Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006; 12(13):4072-9. DOI: 10.1158/1078-0432.CCR-06-0184. View

13.

Zhu Y, Katz M, Imperato-McGinley J . Natural potent androgens: lessons from human genetic models. Baillieres Clin Endocrinol Metab. 1999; 12(1):83-113. DOI: 10.1016/s0950-351x(98)80478-3. View

14.

Velasco A, Gillis K, Li Y, Brown E, Sadler T, Achilleos M . Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology. 2004; 145(8):3913-24. DOI: 10.1210/en.2004-0311. View

15.

Fang Y, Brass A, Hoyle D, Hayes A, Bashein A, Oliver S . A model-based analysis of microarray experimental error and normalisation. Nucleic Acids Res. 2003; 31(16):e96. PMC: 169988. DOI: 10.1093/nar/gng097. View

16.

Smith C, Ballard S, Worman N, Buettner R, Masters J . 5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab. 1996; 81(4):1361-6. DOI: 10.1210/jcem.81.4.8636334. View

17.

Kothapalli R, Yoder S, Mane S, Loughran Jr T . Microarray results: how accurate are they?. BMC Bioinformatics. 2002; 3:22. PMC: 126254. DOI: 10.1186/1471-2105-3-22. View

18.

Lazier C, Thomas L, Douglas R, Vessey J, Rittmaster R . Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate. 2004; 58(2):130-44. DOI: 10.1002/pros.10340. View

19.

Bartsch G, Rittmaster R, Klocker H . Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002; 19(6):413-25. DOI: 10.1007/s00345-002-0248-5. View

20.

Bramson H, Hermann D, Batchelor K, Lee F, James M, Frye S . Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997; 282(3):1496-502. View